Hydroxocobalamin
Brand names: Cobalin-H, Neo-Cytamen, Cyanokit (cyanide antidote)
Hydroxocobalamin is a form of vitamin B12 given by intramuscular injection to treat and prevent vitamin B12 deficiency, including pernicious anaemia and deficiency due to malabsorption.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is converted to the active coenzymes methylcobalamin and adenosylcobalamin, which are required for methionine synthesis and methylmalonyl-CoA metabolism, supporting DNA synthesis, normal erythropoiesis and myelin integrity.
Prescribing in practice
- In severe deficiency, starting treatment can precipitate hypokalaemia as erythropoiesis resumes, so potassium should be considered during the initial response.
- Hydroxocobalamin is preferred over cyanocobalamin in the UK because its longer retention allows less frequent maintenance injections.
- Neurological involvement requires prompt and adequate replacement, and the cause of deficiency should be established as parenteral therapy is usually lifelong in malabsorption.
Monitoring
Monitor the haematological response and, in severe cases, serum potassium during early treatment, with periodic review of ongoing maintenance need.
Counselling the patient
- Vitamin B12 is given as a course of injections and then usually maintained for life when due to absorption problems.
- Tell your clinician about any numbness, tingling or balance problems.
- Keep maintenance injection appointments to prevent the deficiency returning.
Evidence & guidelines
Hydroxocobalamin is the standard UK parenteral vitamin B12 preparation for pernicious anaemia and B12-deficiency states, reflecting its favourable retention compared with cyanocobalamin.
Reference: BCSH Guidelines B12 and Folate Deficiency (2014); BSH (2021); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Corrected Reticulocyte Count / Reticulocyte Production Index · Anaemia
- Ganzoni Equation for Iron Deficiency · Anaemia
- Transferrin Saturation Calculator · Anaemia / Iron Studies
- CTCAE Grading for Anaemia · Toxicity Grading
- Iron Deficiency Anaemia Calculator · Anaemia Assessment
- Reticulocyte Production Index (RPI) · Anaemia Assessment
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO